In Q3 of fiscal 2026, the quarter ended Sep 27, 2026, Quidelortho Corp generated $19.6 million of cash from operations, up 143.1% from the same quarter a year earlier. It spent $21.0 million on capital expenditures. Free cash flow was negative, at -$1.4 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 27, 2026
|
Q3 FY2026
Sep 27, 2026
|
Q2 FY2026
Jun 28, 2026
|
Q1 FY2026
Mar 29, 2026
|
Q4 FY2025
Dec 28, 2025
|
Q3 FY2025
Sep 28, 2025
|
Q2 FY2025
Jun 29, 2025
|
Q1 FY2025
Mar 30, 2025
|
Q4 FY2024
Dec 29, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
462
+5.2%
|
120
+6.7%
|
117
+5.8%
|
113
+5.4%
|
112
+2.9%
|
112
-0.9%
|
110
-5.0%
|
107
-6.8%
|
109
-5.3%
|
| Stock-based compensation |
46
+1.8%
|
12
+12.1%
|
12
-6.2%
|
11
-7.8%
|
11
+12.5%
|
11
-13.0%
|
13
+14.3%
|
12
+28.9%
|
10
-22.0%
|
| Operating cash flow |
8
-78.6%
|
20
+143.1%
|
-111
-136.3%
|
-33
-150.3%
|
132
+107.1%
|
-46
-138.6%
|
-47
+52.2%
|
66
+9471.4%
|
64
-20.8%
|
| Investing | |||||||||
| Capital expenditures |
125
-34.5%
|
21
-58.0%
|
26
-32.0%
|
34
-39.5%
|
44
-5.7%
|
50
+7.5%
|
38
+6.2%
|
56
-15.0%
|
47
-2.9%
|
| Investing cash flow |
-212
-17.0%
|
-21
+61.2%
|
-107
-225.2%
|
-34
+39.5%
|
-50
-30.9%
|
-54
+4.6%
|
-33
+6.5%
|
-56
-178.2%
|
-38
+31.2%
|
| Financing | |||||||||
| Debt repaid |
64
|
21
-99.1%
|
20
-45.6%
|
22
-37.8%
|
2
|
2,216
+67039.4%
|
36
-30.5%
|
36
-30.6%
|
—
|
| Financing cash flow |
271
+176.7%
|
44
-4.1%
|
201
+94.2%
|
38
+113.6%
|
-11
+83.9%
|
46
+274.9%
|
103
-36.4%
|
18
+195.1%
|
-69
-19.2%
|
| Change in cash | |||||||||
| Effect of exchange rate |
1
+900.0%
|
0
+200.0%
|
0
-70.0%
|
0
-100.0%
|
0
+120.8%
|
-0
-114.3%
|
1
+225.0%
|
2
+254.5%
|
-2
-214.3%
|
| Net change in cash |
68
+248.8%
|
43
+180.2%
|
-17
-169.4%
|
-29
-202.4%
|
72
+257.6%
|
-54
-246.8%
|
24
-14.0%
|
29
+170.9%
|
-46
-49.7%
|
| Free cash flow |
-117
+23.9%
|
-1
+98.5%
|
-136
-61.4%
|
-67
-812.8%
|
87
+429.7%
|
-96
-233.8%
|
-84
+36.7%
|
9
+114.1%
|
16
-48.1%
|
| Per share | |||||||||
| Free cash flow per share |
-1.71
+24.7%
|
-0.02
+98.5%
|
-1.99
-60.0%
|
-0.98
-805.5%
|
1.28
+425.0%
|
-1.40
-232.4%
|
-1.25
+37.3%
|
0.14
+113.9%
|
0.24
-48.7%
|
| Ratios | |||||||||
| Free cash flow margin |
-4.52%
|
-0.23%
|
-21.57%
|
-10.81%
|
12.08%
|
-13.64%
|
-13.73%
|
1.36%
|
2.33%
|
| Capital expenditures to revenue |
4.82%
|
3.39%
|
4.04%
|
5.49%
|
6.15%
|
7.14%
|
6.11%
|
8.11%
|
6.67%
|
| Stock-based compensation to revenue |
1.75%
|
1.94%
|
1.90%
|
1.73%
|
1.49%
|
1.53%
|
2.09%
|
1.67%
|
1.36%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QDEL (Nasdaq)
- Fiscal year ends
- January 1
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1906324
- Former names
- Coronado Topco, Inc. (until Apr 11, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.